Company invites individual and institutional investors as well as advisors to log-on to view presentation
VANCOUVER, British Columbia and MENLO PARK, Calif., June 9, 2014 /CNW/ - DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma"), a clinical-stage company advancing breakthrough cancer therapeutics, located in Vancouver, British Columbia and Menlo Park, Calif., announced today that the June 5th presentation from Jeffrey Bacha, B.Sc., MBA, president & CEO, is now available for on-demand viewing at RetailInvestorConferences.com.
LINK: http://retailinvestorconferences.com > red "register/ watch event now" button
DelMar Pharmaceuticals, Inc.'s presentation will be available 24/7 for 90 days. Investors and advisors may download shareholder materials from the "virtual trade booth" for the next three weeks.
About DelMar Pharmaceuticals, Inc.
DelMar Pharmaceuticals (OTCQB: DMPI) was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for recurrent glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute (NCI), and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.
For more information, please visit http://www.delmarpharma.com or follow us on Twitter @DelMarPharma or Facebook.com/DelMarPharma.
Since 2010, RetailInvestorConferences.com, created by BetterInvesting (NAIC) PR Newswire and MUNCmedia, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.
Safe Harbor Statement
Any statements contained in this update that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.
SOURCE: DelMar Pharmaceuticals, Inc.
For further information:
DelMar: Jeffrey A. Bacha, President & CEO, (604) 629-5989; Booke & Company Investor Relations, email@example.com; RetailInvestorConferences.com: Bradley H. Smith, Director of Marketing, IR and Compliance Services, PR Newswire, +1.201.947.7157, firstname.lastname@example.org